- For Print
- February 28, 2011
Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito) announced today that it has decided to delay the National Health Insurance (NHI) drug price registration and launch of NerBloc® Intramuscular Injection 2500 Units (“NerBloc®”), a botulinum toxin type B neuromuscular-blocking agent that was approved in Japan for the treatment of cervical dystonia on January 21, 2011. The company has deemed that under current circumstances it cannot ensure a stable supply of NerBloc® due to manufacturing capacity-related issues that have arisen at the fill finish site contracted by the supplier, and thus has made the decision to delay its plans until it can confirm that a supply system capable of delivering a stable supply of the product is in place.
As the Japan marketing authorization holder of NerBloc®, Eisai expresses its deep regret for this delay, however, the company remains committed to resolving these issues in order to bring this product to patients and healthcare professionals as early as possible.
Public Relations Department,
Eisai Co., Ltd.